Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Next Generation Drug Conjugates Market Expected to Grow Between 2025 And 2029?
The market size for next-generation drug conjugates has experienced a swift expansion in the past few years. Its growth is projected to reach $2.47 billion in 2025, up from $2.15 billion in 2024, boasting a compound annual growth rate (CAGR) of 14.8%. Past growth can be linked to advanced comprehension of tumor biology, the effectiveness of initial drug conjugates, a rise in oncology prevalence, boosted investment and funding, complemented by heightened patient advocacy and awareness initiatives.
We can anticipate a significant acceleration in the market size for next generation drug conjugates in the coming years. It is predicted to reach a market valuation of $4.41 billion by 2029, growing at a compound annual growth rate (CAGR) of 15.6%. The expansion during the forecast period can be credited to the emergence of combination therapies, growth in clinical research, focus on uncommon diseases, strategic partnerships, and the development of bioinformatics tools. The predictive timeline also identifies key trends such as progress in monoclonal antibody technology, the use of JAK inhibitors in combination therapies, the application of artificial intelligence in drug discovery, the emergence of biosimilars, and the advancement in subcutaneous formulation techniques.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19124&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Next Generation Drug Conjugates Market?
The increasing incidence of cancer is predicted to fuel the expansion of the next-generation drug conjugates market. Cancer is a group of illnesses marked by the uncontrollable proliferation and dissemination of abnormal cells in the body. The uptick in cancer cases is mainly due to aging demographics, lifestyle choices, environmental exposures, enhanced detection, genetic factors, and infectious agents. Next-generation drug conjugates contribute to cancer reduction by administering targeted treatments directly to the cancerous cells, thereby amplifying the effectiveness of the treatment while reducing harm to healthy tissues. For instance, a report released by the Australian Institute of Health and Welfare in August 2024, a national Australian agency for health and welfare data and statistics, forecasts that there will be around 209,000 new cancer diagnoses in Australia by 2034. This is a notable surge from the predicted 169,000 cases in 2024, signifying the influence of an expanding population and escalating cancer rates. Hence, the growing rate of cancer is steering the development of the next-generation drug conjugates market.
Which Key Market Segments Comprise the Next Generation Drug Conjugates Market and Drive Its Revenue Growth?
The next generation drug conjugates market covered in this report is segmented –
1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate
2) By Targeting Ligand Type: Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles
3) By Payload Type: Oligonucleotide, Radionuclide, Peptide, Small Molecule
4) By Therapy: Monotherapy, Combination Therapy
5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications
Subsegments:
1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues, Radiolabeled Peptides
2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates, ShRNA Ligand Conjugates
3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates, Antisense Oligonucleotide Ligand Conjugates
4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates, Therapeutic Peptide Conjugates
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=19124&type=smp
Which Areas Are Leading Regions in the Next Generation Drug Conjugates Market Expansion Across the Globe?
North America was the largest region in the next generation drug conjugates market in 2024. The regions covered in the next generation drug conjugates marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in theNext Generation Drug Conjugates Market Over the Coming Years?
Key players in the next-generation drug conjugates market are employing a strategy of strategic partnerships to boost their research and development capabilities, expedite product innovation, and broaden their market dominance. Strategic partnerships involve corporations capitalizing on each other’s strengths and resources in a bid to reap mutual gains and achieve shared success. For example, in November 2023, Prelude Therapeutics Incorporated, a clinical-stage precision oncology firm from the US, forged a partnership with Canada’s biotech firm AbCellera Biologics Inc. The aim was to create first-in-class precision antibody-drug conjugates (ADCs) for oncology. The collaboration will focus primarily on discovering, developing, and commercializing ground-breaking antibody-drug conjugates (ADCs), beginning with a program that focuses on a SMARCA degrader tied to a new antibody. This approach seeks to extend the therapeutic uses of Prelude’s SMARCA2 selective degraders to a larger pool of patients, specifically those suffering from cancers not linked to SMARCA4 mutations.
View the full report here:
How Is the Next Generation Drug Conjugates Market Conceptually Defined?
Next-generation drug conjugates refer to advanced formulations of drug conjugates designed to improve the efficacy and safety of targeted therapies. Next-generation drug conjugates utilize advanced targeting technologies and enhanced payloads to deliver potent therapies directly to disease cells with greater precision and reduced side effects.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19124
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
